Currently Viewing:
Currently Reading
Accelerated Approval for Nivolumab for DNA RepairóDeficient Advanced CRC
August 02, 2017 – Surabhi Dangi-Garimella, PhD
Enasidenib Approved for IDH2-Mutated Patients With Relapsed/Refractory AML
August 01, 2017 – Surabhi Dangi-Garimella, PhD
Study Finds Rising Insurer Approvals for Cancer Clinical Trials Since ACA
August 01, 2017 – Christina Mattina
The FDA's Roadmap for More Stringent Tobacco Regulation
July 31, 2017 – Surabhi Dangi-Garimella, PhD
What We're Reading: Bipartisan Health Fix; Superbug in Hospitals; Oregon Medicaid Benefits
July 31, 2017 – AJMC Staff
Continued Statin Use Following Adverse Reaction May Reduce Incidence of Death and CVD Events
July 30, 2017 – Alison Rodriguez
FDA Expands Approval of Yervoy for Metastatic Melanoma in Pediatric Patients
July 30, 2017 – Alison Rodriguez
JAMA: Opioids Should Not Be Eliminated to Treat Chronic Pain
July 29, 2017 – Alison Rodriguez
Breakthrough Therapy Designation for Venetoclax in AML
July 28, 2017 – AJMC Staff

Accelerated Approval for Nivolumab for DNA RepairóDeficient Advanced CRC

Surabhi Dangi-Garimella, PhD
The approval follows a review of phase 2 results from CheckMate-142.
Pediatric and adult patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine and oxaliplatin or irinotecan, have an additional treatment option: the programmed death-1 inhibitor, nivolumab (Opdivo). The FDA requires the drug’s manufacturer, Bristol-Myers Squibb, to conduct confirmatory trials to ensure clinical benefit for continued approval of this indication.

The clinical data submitted for review included phase 2 results from CheckMate-142, a multicenter (31 sites across 8 nations), single-arm study that evaluated nivolumab in 74 patients with dMMR or MSI-H mCRC who had progressed on or after fluoropyrimidine-oxaliplatin or irinotecan-based chemotherapy. The study also included patients who were intolerant to any of these treatments. Seventy-four patients were administered 3 mg/kg nivolumab every 2 weeks, a much higher dose than the recommended 240 mg administered as an intravenous infusion over 60 minutes every 2 weeks.

The study noted an objective response rate of 28% with nivolumab (95% CI, 17-42) in patients who had received prior treatment with a fluoropyrimidine, oxaliplatin, or irinotecan—this included a 1.9% complete response rate and a 26% partial response rate. In the entire patient cohort, 32% responded to nivolumab (95% CI, 22-44), which included a 2.7% complete response rate and a 30% partial response rate. Median duration of response was not reached in the overall population or in the pretreated subgroup.

All responders were alive, and 8 had responses lasting 12 months or longer (event rate 86%, 95% CI, 62–95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (6 [8%]) and amylase (2 [3%]). Twenty-three patients (31%) died during the study, but none of these deaths were deemed to be treatment related by the investigator.

“Patients with metastatic colorectal cancer who have dMMR or MSI-H tumors are less likely to respond to conventional chemotherapy,” said Heinz-Josef Lenz, MD, FACP, University of Southern California. “While the challenges of treating these patients have been significant, tumors characterized by these biomarkers are immunogenic. Therefore, advances in immunotherapy research are encouraging in presenting new treatment options for appropriate patients with MSI-H metastatic colorectal cancer.”

MMR or MSI testing is a recommendation in the National Comprehensive Cancer Network Guidelines for patients with a personal history of colon or rectal cancer. Nivolumab has been included as a category 2A treatment option in patients with dMMR or MSI-H CRC as second-line or third-line treatment.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up